



## General description

Rituximab is a monoclonal antibody used in treatment protocols for lymphomas and leukaemia, as well as various autoimmune inflammatory diseases.

INN	Rituximab
ATC codes	L01FA01
Medicine type	Biological agent
EML status history	First added in 2015 (TRS 994) for Diffuse large B-cell lymphomas Added in 2015 (TRS 994) for Chronic lymphocytic leukaemia or small lymphocytic lymphoma Added in 2015 (TRS 994) for Follicular lymphoma Added in 2023 (TRS 1049) for Multiple sclerosis Added in 2023 (TRS 1049) for Burkitt lymphoma including Burkitt leukaemia
Wikipedia	<a href="#">Rituximab</a> 
DrugBank	<a href="#">Rituximab</a> 

## Recommendations

### Section Targeted therapies

Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial

#### Indications

Diffuse large B-cell lymphomas

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Follicular lymphoma

Burkitt lymphoma including Burkitt leukaemia

### Section Medicines for multiple sclerosis

Parenteral > General injections > IV: 500 mg per 50 mL in 50 mL vial

#### Indications

Multiple sclerosis

